BMJ Open

Glycaemic control efficacy of oral antidiabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis

Yongliang Jia,¹ Yaoguang Lao,¹ Siu-wai Leung¹,²

ABSTRACT

Introduction: Past studies of network meta-analysis focused on evaluating drug combinations in treating type 2 diabetes but not on evaluating antidiabetic drugs in monotherapy. Clinical guidelines (eg, NICE (National Institute of Health and Care Excellence) clinical guidelines 66 and 87) were based only on the findings of individual clinical trials and pairwise meta-analysis in evaluating monotherapy. This study aims to fill this gap of research by conducting a Bayesian network meta-analysis to compare major antidiabetic drugs, including metformin, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin and SGLT-2 (sodium-glucose transporter-2) inhibitors.

Methods and analyses: Randomised controlled trials (RCTs) on the drug therapy of type 2 diabetes with outcome measures including glycosylated haemoglobin or fasting blood glucose will be included. The quality of included RCTs will be evaluated according to the Cochrane Collaboration’s risk of bias tool. Traditional pairwise meta-analysis and Bayesian network meta-analysis will be conducted to compare the efficacies of antidiabetic drugs. Sensitivity analysis on the sample size of RCTs, meta-regression analysis on the follow-up periods, dosages and baselines of outcome measure, contradiction analysis between pairwise and network meta-analyses, and publication bias analysis, will be performed.

Ethics and dissemination: Ethical approval is not required because this study includes no confidential personal data and interventions on the patients. Pairwise and network meta-analyses are based on the published RCT reports of eligible drugs in treating type 2 diabetes. The results of this study will be disseminated by a peer-reviewed publication.

Protocol registration number: PROSPERO CRD42014010567.

INTRODUCTION

Glycaemic control would prevent microvascular and macrovascular complications of type 2 diabetes.¹,² Several categories of oral antidiabetic drugs including biguanides, thiazolidinediones, sulfonylureas, meglitinides, DPP-4 (dipeptidyl peptidase-4) inhibitors and α-glucosidase inhibitors are available for monotherapy of type 2 diabetes. Efficacies of these drugs should be monitored for post-marketing evaluation and for updating of clinical guidelines. However, the latest National Institute for Health and Care Excellence (NICE) guidelines³–⁴ for treating type 2 diabetes only included those randomised control trials (RCTs) and their meta-analyses published before 2010.

Even if the clinical guidelines were up to date, there are still gaps to be filled among the current pieces of evidence for the glycaemic control efficacy of oral antidiabetic drugs. First, the current evidence for oral antidiabetic drug efficacies was only limited to a number of head-to-head RCTs and meta-analyses, including the most comprehensive study by the Agency for Healthcare Research and Quality,⁵ and does not cover all possible comparisons among individual drugs. In this situation, network meta-analysis (NMA) that can integrate the evidence from direct and indirect comparisons,⁶ would be applicable. Second, efficacy ranking of the oral antidiabetic drugs was still unknown. The drug recommendation by clinical guidelines was not based on comprehensive and systematic studies for comparing multiple drugs. This gap also suggests an imminent need for NAM that can rank all evaluated interventions.⁷
While NAM was used in comparing the efficacies of oral antidiabetic drugs, the available network meta-analyses evaluated only treatments combined with metformin. The monotherapy efficacies of individual drugs have not been studied by NAM.

This study conducted a Bayesian NAM to compare the glycaemic control efficacy of popular oral antidiabetic drugs, including metformin, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin and SGLT-2 (sodium-glucose transporter-2) inhibitors.

**OBJECTIVE**

The objective of this study is to compare efficacies of popular antidiabetic drugs by Bayesian NAM on RCTs.

**METHODS AND ANALYSIS**

**Design**

Systematic review and Bayesian NAM.

**Information sources**

Clinical trial reports will be searched from PubMed and Cochrane Library.

**Search strategies**

Drug names, synonyms of type 2 diabetes (eg, type 2 diabetes, type II diabetes and non-insulin-dependent diabetes) and “random*” will be used as keywords to search titles or abstracts for eligible RCTs from major databases including PubMed, Cochrane Library, ScienceDirect and EMBASE, as well as Food and Drug Administration medical reviews and clinicaltrials.gov website. The search is scheduled between August and October in 2014. For example, the following search strategy will be used in searching PubMed:

1. metformin
2. type 2 diabetes
3. random*
4. 1 in title or abstract
5. 2 in title or abstract
6. 3 in title or abstract
7. 4 and 5 and 6

**Eligibility criteria**

The retrieved reports will be screened according to the checklist of eligibility (see online supplementary appendix 1) and the eligibility criteria shown below including participants, interventions, controls, types of study and other criteria.

**Participants**

*Inclusion*: The participants must be adults, aged at least 18 years, suffering from and requiring treatment for type 2 diabetes. *Exclusion*: The participants suffering from other diabetic disease conditions or aged under 18 years.

**Interventions**

*Inclusion*: Any RCT that evaluates the efficacy of these drugs. *Exclusion*: Any RCT that evaluates other or combined treatments of multiple drugs or placebo.

**Controls**

*Inclusion*: Any RCT that evaluates the efficacy of these drugs other than the drug of intervention or placebo. *Exclusion*: Any RCT that evaluates other drugs or combined treatments of multiple drugs.

**Types of study**

*Inclusion*: Only RCTs will be included. *Exclusion*: Observational cohort and case–control studies, case reports, experimental studies and reviews will be excluded.

**Other criteria**

Other inclusion criteria: The RCTs must report complete efficacy data of glycosylated haemoglobin (HbA1c) or fasting blood glucose (FPG) of each treatment. Follow-up periods or durations in RCTs are at least 4 weeks. Other exclusion criteria are (1) duplicated or redundant studies and (2) combined treatments with multiple drugs.

**Study selection**

Reviewers will screen all titles or abstracts or full texts for database records independently according to the eligibility criteria. Disagreements between reviewers will be resolved by consensus. Selection process of relevant studies retrieved from databases will be shown in a PRISMA-compliant flow chart (figure 1).

**Data extraction and quality assessment**

Data of the study characteristics and the clinical outcome measures will be extracted. The data extracted from the RCTs are: (1) authors; (2) publication year; (3) baseline of outcome measures; (4) sample sizes; (5) interventions of both arms; (6) dosages of both arms and (7) treatment outcome measures including HbA1c and FPG. The data will be standardised (table 1). The quality of eligible studies will be evaluated according to the Cochrane Collaboration’s risk of bias tool for assessing risk of bias (table 2). Radar chart (or star chart) will be used to summarise the results.

**Outcome measures**

Outcome measures of antidiabetic efficacy include mean changes of HbA1c (primary outcome) and FPG (secondary outcome) from baseline and their corresponding variation.

**Statistical analysis**

Pairwise meta-analysis of the included RCTs with random effect model due to the expected heterogeneity will be conducted. Mean difference (MD) will be used to synthesis the continuous outcome data: mean changes from baseline of the HbA1c (%) and FPG (mol/L) in both arms. $I^2$ was used to estimate the
heterogeneity. Networks will be generated to visualise the results of pairwise meta-analysis and the current evidence from the included RCTs.

NAM based on the Bayesian hierarchical model will be performed to compare the efficacy of selected drugs. Placebo will be used as common comparison in NMA. Relative MD to the placebo will be output to assess the efficacy. The probability of each drug being ranked in each position based on HbA1c will be computed. Kendall’s test will be used to test the correlation between the relative MD and the ranking position.

Sensitivity analysis based on the sample size of the RCTs will be conducted when RCTs with sample size less than 50 are excluded. Sensitivity analysis will also be conducted on different baselines. Meta-regression analyses will be conducted on the different follow-up periods and dosages for drugs of the included RCTs. Begg’s and Egger’s tests will be used to evaluate the publication bias. Agreement will be computed to assess the consistency between pairwise and network meta-analyses.

R software will be used to implement the analysis workflow. Package “metafor” will be used to conduct pairwise meta-analysis. Package ‘igraph’ will be used to visualise the networks. Package ‘fmsb’ will be used to visualise the results of risk of bias assessment. Package ‘GeMTC’, ‘R2WinBUGS’ in R and WinBUGS will be used to conduct NAM. Package ‘ggplot2’ will be used to visualise the distribution of ranking probability distribution. p Values lower than 0.05 will be considered statistically significant.

**ETHICS AND DISSEMINATION**

**Ethical issues**

No ethical approval is required because this study includes no confidential personal data or interventions with the patients.

---

**Table 1** Summary of the included RCTs

<table>
<thead>
<tr>
<th>Study</th>
<th>Baseline</th>
<th>Sample size</th>
<th>Treatment duration</th>
<th>Drug 1 dosage</th>
<th>Drug 2 dosage</th>
<th>Drug 3 dosage</th>
<th>HbA1c</th>
<th>FPG</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCT 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>…</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FPG, fasting blood glucose; HbA1c, glycosylated haemoglobin; RCT, randomised controlled trial.
This protocol has been registered (Registration number: CRD42014010567) with the PROSPERO (International Prospective Register of Systematic Reviews). The procedures of this systematic review and NAM will be conducted in accordance with the PRISMA-compliant guideline. The results of this systematic review and NAM will be submitted to a peer-reviewed journal for publication.

### Contributors
S-wL conceived the study. S-wL, YL and YJ designed the protocol. YL and YJ tested the feasibility of the study. YJ, YL and S-wL wrote the protocol and approved the final manuscript.

### Funding
The study is part of the ‘Open systematic reviewing of clinical trials’ project supported by a research grant (MYRG190-Y3-L3-ICMS11-LSW) received from the University of Macau.

### Competing interests
None.

### Provenance and peer review
Not commissioned; externally peer reviewed.

---

### Table 2  Randomised controlled trial (RCT) quality assessment according to the Cochrane Collaboration’s risk of bias tool

|                     | RCT 1 | RCT 2 | RCT 3 | RCT 4 | RCT 5 | ...
|---------------------|-------|-------|-------|-------|-------|-------
| Random sequence generation |       |       |       |       |       |       |
| Allocation concealment |       |       |       |       |       |       |
| Blinding of participants and personnel |       |       |       |       |       |       |
| Blinding of outcome assessment |       |       |       |       |       |       |
| Incomplete outcome data |       |       |       |       |       |       |
| Selective outcome data |       |       |       |       |       |       |
| Sources of bias |       |       |       |       |       |       |

Each item of included RCT will be evaluated at low risk, unclear risk and high risk of bias, based on the Cochrane Collaboration’s risk of bias tool.

---

### References